Tagged with OP

EFPIA The European Commission recently announced a new industrial strategy and pharmaceutical roadmap, largely focused on revising legislation dating back nearly two decades, with the aim of laying out a concrete plan by the end of 2020. The commission’s priority is to revitalize medical innovation in Europe, a chief concern voiced…

Belgium Bertrand Duquesne, managing director of Boiron Belgium, elaborates on the challenges being faced by homeopathy manufacturers in western Europe and explains how the company and its peers are create dialogue about these products in the country with the newly formed Homeopathy Belgium Industry Association.   In 2017, 44 percent of…

Opinion AAM Interim President Jeff Francer outlines the vital role that biosimilar and generics firms will play in filling supply chain gaps during the ongoing coronavirus pandemic.   Like the rest of society, executive and scientific teams working in the US generic and biosimilar pharmaceutical industries have never experienced anything quite…

Czech Republic The Czech Republic boasts a solid clinical research infrastructure and a supportive regulatory environment, meaning that it stands out as one of Central and Eastern Europe’s top destinations for clinical trials. However, a decline in the number of clinical trials in recent years means that Czech stakeholders are looking to…

Mexico Earlier in 2020, PharmaBoardroom sat down with several key stakeholders in the Mexican healthcare and life sciences industry, from the leaders of multinational affiliates, start-up entrepreneurs, association heads, and key opinion leaders. Here, we round up three of their most talked about topics.   Government  One of the most talked-about…

Opinion Blue Spoon Consulting’s John G. Singer* provides a thought-provoking outline of how the global health economy needs to evolve a new ‘systems framework’ to deal with the complexity and interconnectedness of healthcare today.   We need to unleash a new set of capabilities designed by a different level of thinking…

Belgium In its ruling of 30 January 2020, the Court of Justice of the European Union (‘CJEU’) has clarified for the first time the criteria governing whether a reverse payment settlement agreement concerning a dispute between the holder of a pharmaceutical patent (‘originator’) and a manufacturer of generic medicines (‘generic’) is…

Global To celebrate International Women’s Day 2020, PharmaBoardroom brings you insights from some of the most inspirational female industry leaders we have had the privilege of talking to over the past 12 months.   Janet Woodcock, Director, Center for Drug Evaluation and Research (CDER), US FDA     Science really can…

Europe EFPIA’s Nathalie Moll highlights how Europe can reverse its decline in the global medical research standings and once again make the continent a world leader in medical innovation.   If the content of the Pharmaceutical Strategy undermines the ambition of the Industrial Strategy then there is a very real, immediate…

Canada Dr Neil Cashman looks at the potential impact of US FDA approval for Biogen’s aducanumab on the search for Alzheimer’s Disease (AD) treatments, and how Canada is playing a leading role in the development of the next generation of AD therapies.   We’re at the advent of a potential landmark…

Opinion Francois Sandre, Head of Asia & JPAC for Sanofi Pasteur outlines the importance of a sustainable global vaccine ecosystem and why a value-based approach, ensuring a steady supply of vaccines, and encouraging innovation are all crucial to meeting the public health goals of the future.   Vaccination is one of…

Opinion Regular PharmaBoardroom contributor David Crean looks at how the ongoing global coronavirus outbreak has impacted the global economy, how the biopharmaceutical industry is responding, and what the longer-term consequences of the crisis and responses to it will be.   The latest disruptor to global health and the economy is the…